
Tenet Healthcare Corporation (NYSE:THC – Free Report) – Research analysts at Zacks Research lifted their Q1 2027 earnings estimates for shares of Tenet Healthcare in a research report issued on Thursday, November 19th. Zacks Research analyst Team now anticipates that the company will post earnings of $4.75 per share for the quarter, up from their previous estimate of $4.63. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Tenet Healthcare’s current full-year earnings is $22.29 per share. Zacks Research also issued estimates for Tenet Healthcare’s Q2 2027 earnings at $5.01 EPS, Q3 2027 earnings at $4.87 EPS, FY2027 earnings at $19.77 EPS, Q1 2028 earnings at $4.72 EPS, Q2 2028 earnings at $5.56 EPS, Q3 2028 earnings at $5.04 EPS and FY2028 earnings at $20.98 EPS.
Tenet Healthcare (NYSE:THC – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $6.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.68 by $1.96. Tenet Healthcare had a net margin of 13.09% and a return on equity of 28.22%. The firm had revenue of $6.28 billion for the quarter, compared to analyst estimates of $5.49 billion. During the same quarter in the previous year, the business posted $3.70 earnings per share. The firm’s quarterly revenue was up 6.5% compared to the same quarter last year.
Read Our Latest Research Report on THC
Tenet Healthcare Stock Performance
THC opened at $263.34 on Friday. The firm has a market cap of $20.96 billion, a P/E ratio of 7.64, a price-to-earnings-growth ratio of 1.41 and a beta of 1.20. The business’s fifty day moving average is $268.86 and its 200-day moving average is $226.99. Tenet Healthcare has a 52-week low of $157.58 and a 52-week high of $301.44. The company has a debt-to-equity ratio of 1.76, a quick ratio of 1.52 and a current ratio of 1.58.
Insider Buying and Selling
In other Tenet Healthcare news, Director Richard Mark sold 10,000 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $263.42, for a total value of $2,634,200.00. Following the completion of the transaction, the director owned 25,121 shares in the company, valued at $6,617,373.82. This represents a 28.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director J. Robert Kerrey sold 12,010 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $263.72, for a total transaction of $3,167,277.20. Following the completion of the sale, the director owned 4,794 shares of the company’s stock, valued at $1,264,273.68. This trade represents a 71.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 99,462 shares of company stock valued at $27,081,234 over the last three months. Company insiders own 0.97% of the company’s stock.
Hedge Funds Weigh In On Tenet Healthcare
A number of hedge funds and other institutional investors have recently made changes to their positions in THC. V Square Quantitative Management LLC acquired a new stake in shares of Tenet Healthcare during the 3rd quarter worth approximately $26,000. Mather Group LLC. grew its holdings in Tenet Healthcare by 126.9% during the 3rd quarter. Mather Group LLC. now owns 118 shares of the company’s stock worth $30,000 after acquiring an additional 66 shares during the period. Trust Co. of Vermont bought a new stake in shares of Tenet Healthcare during the 2nd quarter valued at $37,000. MADDEN SECURITIES Corp bought a new stake in shares of Tenet Healthcare during the 3rd quarter valued at $38,000. Finally, Compass Financial Management LLC acquired a new position in shares of Tenet Healthcare in the 2nd quarter valued at $57,000. 95.44% of the stock is owned by institutional investors.
Tenet Healthcare News Summary
These are some of the THC news items that stood out recently:
- Positive Sentiment: Zacks Research raised its EPS forecasts across several quarters and full years. Its FY2027 estimate increased to $19.77 from $18.91, and its FY2028 estimate rose to $20.98 from $20.09. Higher analyst expectations may support investor sentiment by suggesting improved earnings prospects. Tenet Healthcare analyst estimates
- Positive Sentiment: A separate Zacks article characterized THC as a top-ranked momentum stock, a potentially favorable signal for investors focused on price trends. Zacks momentum-stock article
- Neutral Sentiment: Despite the estimate increases, Zacks Research maintained a “Hold” rating, indicating it did not make a more bullish recommendation. Tenet Healthcare analyst information
Tenet Healthcare Company Profile
Tenet Healthcare Corporation is a U.S.-based healthcare services company that operates acute care hospitals and provides related inpatient and outpatient services. Its hospitals offer services across areas such as emergency care, surgery, imaging and specialty treatment. Through its subsidiary United Surgical Partners International (USPI), Tenet also operates ambulatory surgery centers and surgical hospitals, providing outpatient surgical and procedural care. The company’s Conifer Health Solutions business provides revenue cycle management and other administrative services to healthcare providers.
Featured Articles
- Five stocks we like better than Tenet Healthcare
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Tenet Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenet Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
